API delivers on guidance despite ‘difficult conditions’

PBS changes and exclusive direct distribution wiped more than $10 million in gross profit, according to FY18 results Australian Pharmaceutical Industries (API) has reported mixed results in its financial year 2018 announcement. Underlying net profit after tax (NPAT) was $54.7 million, up 0.9% on the prior corresponding period. This result is positive after API’s half-year